“That's the first thing that is going to happen and that will likely be a signal to Wall Street that they are missing the point. These companies are extremely healthy in terms of their product development. The small-cap companies are very much undervalued right now and it's going to be somebody's opportunity.”
“The irony is that this industry took a hit at a time when nearly 300 biotech drugs and vaccines are in human clinical trials, ... The pipelines have never been fuller. I think it'll take investors a little more time to recognize that before small-cap stocks will come back.”
“The irony is that this industry took a hit at a time when nearly 300 biotech drugs and vaccines are in human clinical trials. The pipelines have never been fuller. I think it'll take investors a little more time to recognize that before small-cap stocks will come back.”
